https://allsci.com/news/regulatory/zumrad-eu-application-pfizer-withdraws-zumrads/ AllScien 2026-09-16T11:12:12.843386Z Pfizer follows AstraZeneca in pulling EU bladder cancer filing after CHMP concerns https://allsci.com/news/regulatory/sys6010-breakthrough-therapy-cspcs-secures-fourth/ AllScien 2026-09-16T10:43:36.102369Z China grants breakthrough status to CSPC’s EGFR ADC in AGA-negative NSCLC https://allsci.com/news/regulatory/zasocitinib-psoriasis-fda-grants-priority-review/ AllScien 2026-09-16T10:19:45.091592Z Takeda secures FDA Priority Review for oral TYK2 inhibitor zasocitinib https://allsci.com/news/funding/shennon-biotechnologies-raises-usd-12m-to-advance/ AllScien 2026-09-16T08:26:35.022801Z Shennon raises USD 12m to advance three preclinical T-cell engagers https://allsci.com/news/strategic-financing/orvida-pharma-financing-secures-recordati-led/ AllScien 2026-09-16T08:16:28.381645Z Orvida secures Recordati-led financing for ontivatrep in rare genetic skin diseases https://allsci.com/news/licensing-and-partnerships/qurcan-lilly-deal-lands-to-advance-cns-and-pns/ AllScien 2026-09-15T19:59:57.632059Z QurCan lands Lilly deal to advance CNS and PNS nucleic acid therapies https://allsci.com/news/regulatory/maat013-chmp-vote-second-negative-trend-clouds/ AllScien 2026-09-15T19:54:30.590285Z Second negative CHMP trend vote clouds MaaT Pharma's European path for MaaT013 https://allsci.com/news/approvals/bexlutry-fda-approval-approves-curiums/ AllScien 2026-09-15T19:41:37.117184Z FDA approves Curium’s Bexlutry, challenging Novartis’ Lutathera monopoly in GEP-NETs https://allsci.com/news/clinical-trials/expedited-ind-pilot-fda-launches-and-opens/ AllScien 2026-09-15T19:36:14.222575Z FDA opens expedited IND pathway with rolling pre-IND review https://allsci.com/news/corporate-strategy/cellectis-gene-editing-exits-car-t-development-to/ AllScien 2026-09-15T18:10:38.202525Z Cellectis exits CAR-T development to focus on in vivo gene editing for metabolic diseases https://allsci.com/news/venture-financing/ql-biopharmaceutical-financing-completes-series/ AllScien 2026-09-15T17:59:30.886247Z QL Bio completes RMB 30m Series C+ financing to advance metabolic disease pipeline https://allsci.com/news/clinical-trials/dt120-phase-iii-definiums-scores-second/ AllScien 2026-09-15T15:45:54.186979Z Definium’s LSD therapy posts second positive Phase III GAD result https://allsci.com/news/pipe-financing/pds-biotech-financing-secures-usd-113m-initial-1/ AllScien 2026-09-15T14:19:39.847198Z PDS Biotech secures USD 11.3m initial PIPE to fund PDS0301 Phase III protocol submission https://allsci.com/news/business/novo-nordisk-rebrand-adopts-identity-new-culture/ AllScien 2026-09-15T14:08:14.939895Z Novo Nordisk adopts ‘Novo’ identity and new culture framework to sharpen competitiveness https://allsci.com/news/preclinical/gsk-multiple-myeloma-deal-strikes-up-to-usd-750m/ AllScien 2026-09-15T14:00:31.750142Z GSK buys second Chimagen T cell engager in deal worth up to USD 750m https://allsci.com/news/licensing-and-partnerships/transcon-metabolic-rights-ascendis-to-regain-as/ AllScien 2026-09-15T13:49:12.210356Z Novo exits Ascendis TransCon obesity deal, returning once-monthly semaglutide rights https://allsci.com/news/clinical-trials/pipe-307-trial-fails-to-beat-placebo-in-phase-ii/ AllScien 2026-09-15T12:42:30.679827Z J&J reviews PIPE-307 future after second Phase II failure, in MDD https://allsci.com/news/research/nose-to-brain-screening-aptar-and-massachusetts/ AllScien 2026-09-15T12:20:01.879227Z Aptar and MGH develop predictive NAM for nose-to-brain drug delivery https://allsci.com/news/clinical-trials/one04-therapeutics-launches-with-cpv-104-phase-1/ AllScien 2026-09-15T12:02:08.112534Z One04 launches around Eleva’s Factor H program with kidney and AMD expansion plans https://allsci.com/news/public-offerings/tyra-400m-offering-prices-usd-to-fund-late-stage/ AllScien 2026-09-14T17:27:56.738528Z Tyra prices USD 400m offering to fund late-stage push for dabogratinib across three indications https://allsci.com/news/licensing-and-partnerships/onvansertib-license-dispute-cardiff-and-nerviano/ AllScien 2026-09-14T17:19:24.459842Z Cardiff and Nerviano settle onvansertib license dispute ahead of planned Phase III trial https://allsci.com/news/clinical-trials/gensci148-phase-i-trial-registers-for-four-target/ AllScien 2026-09-14T17:09:07.083010Z GenSci registers Phase I trial of four-target retinal fusion protein across three indications https://allsci.com/news/clinical-trials/lpcn-1154-lipocine-starts-second-phase-iii-for/ AllScien 2026-09-14T16:57:20.630010Z Lipocine starts second Phase III for postpartum depression drug after first trial misses endpoint https://allsci.com/news/clinical-trials/alv-100-trial-alveus-launches-phase-ii-preserve/ AllScien 2026-09-14T16:48:40.885766Z Alveus takes aim at post-semaglutide weight regain with ALV-100 https://allsci.com/news/clinical-trials/yy003-phase-ii-revelyxs-clears-hurdle-potential/ AllScien 2026-09-14T15:27:29.206832Z Revelyx reports positive Phase II data for recombinant liquid botulinum toxin https://allsci.com/news/clinical-trials/sab01-clinical-trial-santa-ana-bio-advances/ AllScien 2026-09-14T15:17:20.372731Z Santa Ana Bio takes KIT/Siglec-6 bispecific SAB01 into first-in-human testing https://allsci.com/news/approvals/walvax-mrna-vaccine-china-approves-walvaxs-third/ AllScien 2026-09-14T14:38:05.592234Z China approves Walvax’s third mRNA COVID-19 vaccine, targeting the Omicron JN.1 strain https://allsci.com/news/clinical-trials/risvutatug-rezetecan-cuts-death-risk-54-versus/ AllScien 2026-09-14T13:37:31.112147Z Hansoh/GSK’s risvutatug rezetecan delivers 54% OS risk reduction in relapsed SCLC https://allsci.com/news/clinical-trials/mri-surveillance-sclc-phase-iii-maverick-trial/ AllScien 2026-09-14T13:12:36.033336Z MAVERICK Phase III data support MRI surveillance alone in SCLC https://allsci.com/news/clinical-trials/rybrevant-egfr-exon-20-rybrevants/ AllScien 2026-09-14T12:48:46.484350Z J&J's Rybrevant shows numerical OS gain in PAPILLON, but final analysis misses significance https://allsci.com/news/approvals/joenja-approval-fda-approves-for-children-aged-4/ AllScien 2026-09-14T12:10:17.958370Z Pharming expands Joenja's US indication to children aged 4–11 with APDS https://allsci.com/news/approvals/isembyld-fda-approval-approves-scholar-rocks-as/ AllScien 2026-09-14T11:52:00.103519Z US FDA approves Scholar Rock’s Isembyld as first muscle-targeted SMA therapy https://allsci.com/news/clinical-trials/her2-mutant-lung-cancer-enhertu-cuts-progression/ AllScien 2026-09-14T11:44:13.686888Z Enhertu Phase III win supports first-line expansion in HER2-mutant NSCLC